December 11, 2018
Daiichi Sankyo said on December 10 that its investigational HER2-targeting antibody drug conjugate (ADC) DS-8201 (trastuzumab deruxtecan) delivered an overall response rate (ORR) of 44.2% in patients with HER2 low expressing metastatic breast cancer. According to Japan/US PI data presented...read more